Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder (OAB) Clear all
Completed Phase 3 Interventional Results available

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

NCT01655069
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin succinate suspension
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated Phase 4 Interventional Results available

Tetra-NIRS Clinical Study

NCT00871975
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Urodynamics + TETRA - NIRS
Device
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Dried Cranberry, Placebo Oral Capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional

FemPulse Therapy for Overactive Bladder in Women

NCT03784170
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Woodbury, Minnesota • Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939
View directory record Official record
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Jul 22, 2026, 4:47 AM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

NCT00444925
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine fumarate, placebo, tolterodine tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated No phase listed Observational

PTNS vs Botox of Refractory OAB

NCT04451382
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
OnabotulinumtoxinA (BoNTA), Percutaneous tibial nerve stimulation (PTNS)
Biological · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated Not applicable Interventional

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

NCT05381116
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urge Incontinence
Interventions
Avation System, Sham Avation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Tucson, Arizona • Oak Lawn, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Early Phase 1 Interventional

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

NCT05880862
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
Interventions
Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride
Behavioral · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 99 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 4 Interventional

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Darifenacin, Behavioral therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Timeline
2005 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Jul 22, 2026, 4:47 AM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Early Phase 1 Interventional

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron

NCT03612401
View directory record Official record
Conditions
Spinal Cord Injuries, Neurogenic Bladder, Cognitive Change
Interventions
Mirabegron
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

NCT00454896
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
VESIcare®, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

NCT04103450
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
31
States / cities
Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07195656
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Device Group, Medication Group
Device · Drug
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

BlueWind RENOVA iStim™ System for the Treatment of OAB

NCT03596671
View directory record Official record
Conditions
Treatment of Patients Suffering From Overactive Bladder (OAB)
Interventions
RENOVA iStim™ System
Device
Lead sponsor
BlueWind Medical
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Orange, California • San Diego, California • Norwalk, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Not yet recruiting Phase 4 Interventional

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

NCT06953271
View directory record Official record
Conditions
Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 4:47 AM EDT